Tags : ACCORD Program

COVID-19 Pharma

Bergenbio’s Bemcentinib Selected to be Fast-Tracked Under UK’s ACCORD Program

Shots: Bemcentinib has been selected as the first potential treatment to be fast-tracked under UK’s P-II ACCORD program that rapidly evaluates bemcentinib’s effectiveness in hospitalized UK NHS patients with COVID-19 The study will commence testing of bemcentinib vs SOC in 120 patients across 6 UK NHS hospital trusts with its anticipated results within few months. […]Read More